Travere Therapeutics, Inc.
TVTX
Price:
$10.98
Market Cap:
$839.88M
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in ...[Read more]
Industry
Biotechnology
IPO Date
2012-11-08
Stock Exchange
NASDAQ
Ticker
TVTX
The ROE as of September 2024 (TTM) for Travere Therapeutics, Inc. (TVTX) is -102.43%
According to Travere Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -102.43%. This represents a change of -35.94% compared to the average of -159.89% of the last 4 quarters.
Travere Therapeutics, Inc. (TVTX) Historical ROE (quarterly & annually)
How has TVTX ROE performed in the past?
The mean historical ROE of Travere Therapeutics, Inc. over the last ten years is -64.27%. The current -102.43% ROE has changed 59.37% with respect to the historical average. Over the past ten years (40 quarters), TVTX's ROE was at its highest in in the September 2014 quarter at 191.96%. The ROE was at its lowest in in the June 2024 quarter at -464.84%.
Average
-64.27%
Median
-43.87%
Minimum
-649.88%
Maximum
297.81%
Travere Therapeutics, Inc. (TVTX) ROE by Quarter and Year
Discovering the peaks and valleys of Travere Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 990.21%
Maximum Annual ROE = 297.81%
Minimum Annual Increase = -139.82%
Minimum Annual ROE = -649.88%
| Year | ROE | Change |
|---|---|---|
| 2023 | -55.47% | -91.46% |
| 2022 | -649.88% | 990.21% |
| 2021 | -59.61% | -25.69% |
| 2020 | -80.22% | 21.18% |
| 2019 | -66.20% | 105.18% |
| 2018 | -32.26% | 58.33% |
| 2017 | -20.38% | 30.92% |
| 2016 | -15.56% | -139.82% |
| 2015 | 39.08% | -86.88% |
| 2014 | 297.81% | 61.24% |
Travere Therapeutics, Inc. (TVTX) Average ROE
How has TVTX ROE performed in the past?
The current ROE of Travere Therapeutics, Inc. (TVTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-254.99%
5-year avg
-182.28%
10-year avg
-64.27%
Travere Therapeutics, Inc. (TVTX) ROE vs. Peers
How is TVTX’s ROE compared to its peers?
Travere Therapeutics, Inc.’s ROE is greater than DICE Therapeutics, Inc. (-102.37%), less than Cytokinetics, Incorporated (196.01%), greater than Ventyx Biosciences, Inc. (-61.43%), greater than Cogent Biosciences, Inc. (-66.96%), greater than Nuvalent, Inc. (-28.83%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than Structure Therapeutics Inc. (-20.15%), greater than Revolution Medicines, Inc. (-34.57%), greater than Akero Therapeutics, Inc. (-29.56%), greater than Avidity Biosciences, Inc. (-32.89%), less than Protagonist Therapeutics, Inc. (85.47%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than IDEAYA Biosciences, Inc. (-20.53%), greater than AnaptysBio, Inc. (-255.67%), greater than MeiraGTx Holdings plc (-86.28%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Homology Medicines, Inc. (-100.91%), greater than Legend Biotech Corporation (-23.20%), greater than Vaxcyte, Inc. (-30.07%), greater than Apellis Pharmaceuticals, Inc. (-139.02%),
| Company | ROE | Market cap |
|---|---|---|
| -102.37% | $2.27B | |
| 196.01% | $6.36B | |
| -61.43% | $153.35M | |
| -66.96% | $1.15B | |
| -28.83% | $5.59B | |
| -98.94% | $8.19B | |
| -20.15% | $2.11B | |
| -34.57% | $6.99B | |
| -29.56% | $1.83B | |
| -32.89% | $4.74B | |
| 85.47% | $2.44B | |
| -57.89% | $773.92M | |
| -20.53% | $3.06B | |
| -255.67% | $1.08B | |
| -86.28% | $300.31M | |
| -44.73% | $1.97B | |
| -100.91% | $3.02M | |
| -23.20% | $9.90B | |
| -30.07% | $12.45B | |
| -139.02% | $5.00B |
Build a custom stock screener for Travere Therapeutics, Inc. (TVTX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Travere Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Travere Therapeutics, Inc. (TVTX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Travere Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Travere Therapeutics, Inc.'s ROE?
How is the ROE calculated for Travere Therapeutics, Inc. (TVTX)?
What is the highest ROE for Travere Therapeutics, Inc. (TVTX)?
What is the 3-year average ROE for Travere Therapeutics, Inc. (TVTX)?
What is the 5-year average ROE for Travere Therapeutics, Inc. (TVTX)?
How does the current ROE for Travere Therapeutics, Inc. (TVTX) compare to its historical average?